JAMA Sub-Journal: Eating benefits - no need to keep your mouth shut, innovative drugs are expected to achieve fat reduction and lower blood sugar!

Gastric bypass surgery is a common technique used in metabolic surgery (bariatric surgery) to help patients limit food intake and reduce nutrient absorption, thereby promoting weight loss.
same time, gastric bypass surgery is often considered to have metabolic benefits independent of weight-loss mechanisms, and many studies are exploring the mechanisms that cause this metabolic effect, due to the high rate of type 2 diabetes relief after surgery.
the results of a small trial designed by a team at the University of Washington School of Medicine at NEJM have questioned previous perceptions.
tests showed that metabolic function was significantly improved whether the weight loss target was achieved through surgery or diet.
, however, the three words "hold your mouth" are difficult to say simply.
want to control their appetite in front of the milk tea and chips cake small cage bag, the pain is really no one can stop.
, many researchers are pinning their hopes on bariatric surgery.
latest research shows that weight loss surgery is more effective for long-term control of type 2 diabetes (T2DM) than traditional medicine, with 37.5 percent of patients undergoing surgery maintaining HbA1c until 7.0 percent after 10 years.
study was published in the Lancet.
means there is hope for a cure for type 2 diabetes, which is thought to require lifelong medication.
surgery is, after all, invasing, so many people with diabetes or obesity are afraid.
, on the other hand, there are few options available for this group of people, with only four weight-loss drugs currently approved by the FDA.
recently, phase 2 clinical trials led by a team of experts at Louisiana State University gave us encouraging results.
study, published in the latest issue of jama Network Open, a sub-issue of the Journal of the American Medical Association, reveals the advantages of an innovative drug developed by Novart over bimagrumab compared to other existing weight-loss drugs.
The study, a placebo-controlled, randomized, double-blind Phase II clinical trial, lasted 48 weeks and was designed to assess the effectiveness and safety of bimaru single resistance to improved blood sugar control and other physical indicators in people with type 2 diabetes (T2DM), overweight and obese populations.
the study was conducted in nine locations in the United States and the United Kingdom and included adults with T2DM, BMI between 28-40, and hemoglobin glycation (HbA1c) levels of 6.5% to 10.0%.
participants were randomly treated with intravenous infusions of micamatrol or placebo, once every 4 weeks, for 48 weeks.
at the same time.
both groups received dietary and exercise interventions.
endpoints of the study were total fat mass (FM), and secondary endpoints were changes in muscle mass (LM), waist circumference (WC), HbA1c levels, and weight (BW).
a total of 75 patients were included in the study and assigned to bimaru monoanti (n s 37; 23 females) or placebo (n s 38; 12 females), of whom 58 (77.3%) completed the 48-week study.
(SD) age of the population included in the population was 60.4 (7.7) years, the average (SD) BMI was 32.9 (3.4), and the average (SD) BW was 93.4 6 (14.9) kg; average (SD) FM 35.4 (7.5) kg; average (SD) HbA1c level 7.8% (1.0%).
48 weeks of follow-up, there was a significant improvement over the multiple indicators in the placebo group: 1) more total body fat reduction than in patients in the maroon anti-resistance group: -20.5% vs -0.5% (-7.5) 5kg vs -0.2kg); 2) Weight loss: -6.5% vs -0.8% (-5.9kg vs -0.8kg); 3) BMI improvement more: -2 .19 kg/m2 vs -0.28 kg/m2;4) Waist reduction more: -9.0 cm vs .5cm; 5) blood sugar level (HbA1c) drops by 0.7 6%, placebo group HbA1c increased by 0.04%; 6) thin weight (muscle) increased by 3.6% (1.7 kg), while placebo group lost 0.8% (-0.4 kg).
it's worth noting that in the study, despite dietary guidelines in both groups, and no reduction in actual eating in neither group, the weight loss (6.5 percent) was similar to that of weight-loss drugs that suppressed appetite.
the effects of GLP-1 agonists on T2DM in another recent study, almost doubled the amount of waist circumference reduced by Maru monoantigen.
addition, the exciting findings suggest that there may be a novel drug mechanism that promises to achieve other metabolic health benefits such as weight loss, reduced body fat, increased muscle mass, and improved blood sugar.
: Heymsfield SB, et al. Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial. JAMA Netw Open. 2021 Jan 4; 4(1):e2033457. doi: 10.1001/jamanetworkopen.2020.33457MedSci Original Source: MedSci Original Copyright Notice: All noted on this website "Source: Met Medical" or "Source: MedSci Original" text, images and audio and video materials, copyrights are owned by Metz Medical, without authorization, no media, website or individual may reproduce, authorized to reproduce with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here